Amgen (AMGN) issued 2014 financial guidance which brackets current Street consensus.
Adjusted 2014 EPS: $7.90 to $8.20 versus current consensus $8.14 per share. Amgen said EPS guidance includes $800 million in incremental operating income from the end of the Enbrel profit share arrangement.
Total 2014 revenue: $19.2 billion to $19.6 billion versus current consensus $19.58 billion.
Here are Amgen's fourth-quarter financial results in capsule form:
Adjusted EPS of $1.82 versus $1.68 consensus. Total revenue $5.01 billion versus $4.82 billion consensus.
Key product sales vs. consensus:
Epogen/Aranesp worldwide: $995 million vs $949 million
Neupogen/Neulasta worldwide: $1.4 billion vs $1.4 billion
Enbrel worldwide: $1.2 billion vs $1.2 billion
Kyprolis: $73 million vs. $72 million
The Kyprolis interim analysis of the phase III "ASPIRE" study and phase III "FOCUS" data both expected in the first half of the year.
Romosozumab: "The Company discussed that it has increased the sample size and completed enrollment in its Phase 3 placebo-controlled registrational study in women with postmenopausal osteoporosis."
Blinatumomab: "The Company discussed the recent initiation of a Phase 3 study in patients with relapsed/refractory B-precursor ALL."
Biosimilars: "The Company announced that it has commenced a pivotal study for its biosimilar Avastin (bevacizumab), the third Amgen biosimilar to enter a pivotal trial. The Company announced that enrollment has resumed for its pivotal study for biosimilar Herceptin (trastuzumab)"